Ruigang G. Diao
Yantai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Cost‑effectiveness of first‑line immunotherapy-based combination regimens for advanced renal cell carcinoma in China and the United States.
Journal: Human vaccines & immunotherapeutics
Published: August 22, 2026
Cost-effectiveness analysis of finotonlimab in the treatment of advanced recurrent metastatic head and neck squamous cell carcinoma in China.
Journal: Human vaccines & immunotherapeutics
Published: August 10, 2026
Prediction models for postoperative recurrence in papillary thyroid carcinoma: a systematic review and critical appraisal.
Journal: Frontiers in endocrinology
Published: March 15, 2026
Cost-effectiveness of sugemalimab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced oesophageal squamous cell carcinoma in China.
Journal: BMJ open
Published: February 24, 2026
Cost-effectiveness analysis of sugemalimab plus chemotherapy for the first-line treatment of advanced gastric cancer or gastroesophageal junction cancer.
Journal: Human vaccines & immunotherapeutics
Published: January 12, 2026
Cost-effectiveness of benmelstobart and anlotinib plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer in China.
Journal: Scientific reports
Published: August 15, 2024
The practice and evaluation of antifungal stewardship programs at a tertiary first-class hospital in China.
Journal: BMC infectious diseases
Published: February 18, 2024
Genistein attenuates renal ischemia-reperfusion injury via ADORA2A pathway.
Journal: Human & experimental toxicology
Published: March 18, 2023
Risk score based on three mRNA expression predicts the survival of bladder cancer.
Journal: Oncotarget
Published: February 27, 2017
Last Updated: 09/26/2026